Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970745 | 0.90 | MAPK1 (0.77) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12971130 | 0.89 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL17030265 | 0.89 | MAPK1 (0.57) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL13173608 | 0.88 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970824 | 0.88 | MAPK1 (0.80) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12970961 | 0.88 | MAPK1 (0.77) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL13191753 | 0.86 | MAPK1 (0.83) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12983481 | 0.85 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL19462446 | 0.85 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL12983368 | 0.85 | MAPK1 (0.74) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694067-B1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | TERNA ZENTARIS GMBH (DE) | 2015-08-26 | — | — | EP | claimed |
| US-8791118-B2 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | AETERNA ZENTARIS GMBH (DE) | 2014-07-29 | — | — | US | claimed |
| EP-2694067-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | claimed |
| WO-2012136691-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | claimed |
| US-20120258080-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | claimed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | claimed |
| WO-2017180817-A1 | TREATMENT OF SEPTICEMIA AND ARDS WITH ERK INHIBITORS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-2694067-B1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | TERNA ZENTARIS GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8791118-B2 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | AETERNA ZENTARIS GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791118-B2 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | AETERNA ZENTARIS GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-8791118-B2 | Pyridopyrazines as highly selective ras-Raf-Mek-Erk signal transduction pathway inhibitors | AETERNA ZENTARIS GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2694067-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | Æterna Zentaris GmbH (DE) | 2014-02-12 | — | — | EP | disclosed |
| US-20120258080-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120258080-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2012136691-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ÆTERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258080-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | AETERNA ZENTARIS GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2508184-A1 | Pyridopyrazine derivatives and their use | Æterna Zentaris GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258080-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.